Skip to main content Skip to accessibility
This website is not compatible with your web browser. You should install a newer browser. If you live in Jersey and need help upgrading call the States of Jersey web team on 440099.
Government of Jerseygov.je

Information and public services for the Island of Jersey

L'înformâtion et les sèrvices publyis pouor I'Île dé Jèrri

Prescribed List: Changes from 1 June 2016

A formal published “Ministerial Decision” is required as a record of the decision of a Minister (or an Assistant Minister where they have delegated authority) as they exercise their responsibilities and powers.

Ministers are elected by the States Assembly and have legal responsibilities and powers as “corporation sole” under the States of Jersey Law 2005 by virtue of their office and in their areas of responsibility, including entering into agreements, and under any legislation conferring on them powers.

An accurate record of “Ministerial Decisions” is vital to effective governance, including:

  • demonstrating that good governance, and clear lines of accountability and authority, are in place around decisions-making – including the reasons and basis on which a decision is made, and the action required to implement a decision

  • providing a record of decisions and actions that will be available for examination by States Members, and Panels and Committees of the States Assembly; the public, organisations, and the media; and as a historical record and point of reference for the conduct of public affairs

Ministers are individually accountable to the States Assembly, including for the actions of the departments and agencies which discharge their responsibilities.

The Freedom of Information Law (Jersey) Law 2011 is used as a guide when determining what information is be published. While there is a presumption toward publication to support of transparency and accountability, detailed information may not be published if, for example, it would constitute a breach of data protection, or disclosure would prejudice commercial interest.

A decision made 6 May 2016:

Decision Reference: MD-S-2016-0031

Decision Summary Title :

Prescribed List as of 1 June 2016

Date of Decision Summary:

3 May 2016

Decision Summary Author:

Prescribing Advisor

Decision Summary:

Public or Exempt?

Public

Type of Report:

Oral or Written?

Written

Person Giving

Oral Report:

N/A

Written Report

Title :

PBAC Report 15 March 2016

Date of Written Report:

3 May 2016

Written Report Author:

Prescribing Advisor

Written Report :

Public or Exempt?

Public

Subject:

Changes to be made to the Prescribed List (Jersey) as at 1 June 2015

Decision(s): Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List.  

 

The Minister approved the following addition to the list

  • Cefixime Tablet 200mg

 

 

In addition, the Minister approved new formulations of products already on the Prescribed List

  • Levodopa/carbidopa/entacapone 175/43.75/200 (Stalevo 175) tablet
  • Omeprazole 10mg orodispersible tablets (paediatric use only)
  • Exenatide modified-release 2mg injection (Bydureon)
  • Dimeticone 4% Lotion

 

 

The Minister also approved removal of the following products from the Prescribed List

  • Omega-3 ethyl esters (Omacor)
  • Permethrin 1% crème rinse
  • Further items listed in the accompanying report which have been discontinued

 

The Minister also approved that the following patent expired medicines should be included on the Prescribed list as ‘Generic Only’ items. 

  • Morphine Sulphate modified release tablets

 

The Minister accepted recommendations to make the following minor amendments to the prescribed list

  • Permethrin dermal cream 5% (to specify 5% strength)
  • Sudocrem cream (to remove erroneous 25mg strength)

 

 

Additions to the Prescribed List will be effective from 1 June 2016. Where items are to be removed from the List or to be listed by generic name only, this will be effective from 1 August 2016 and prescriptions for these products will be reimbursed until 31 October 2016.

 

Reason(s) for Decision:

The Pharmaceutical Benefit Advisory Committee (PBAC) met on 15 March 2016 and has provided the Minister with a written report setting out its recommendations in respect of amendments to the Prescribed List.

 

The changes reflect current evidence and expert advice, and ensure that patients in Jersey have access to an appropriate range of modern, safe and effective treatments from their GPs at a proportionate cost to the Fund.

Resource Implications:

The overall impact of the changes represents an anticipated reduction in expenditure of £80,000 to the Health Insurance Fund

Action required:

Policy Principal to issue public notice listing amendments and notify all approved medical practitioners and approved contractors.

 

Signature:

Position:

Minister

Date Signed:

 

Date of Decision (If different from Date Signed):

 

Prescribed List: Changes from 1 December 2016

RECOMMENDATIONS OF THE

PHARMACEUTICAL BENEFIT ADVISORY COMMITTEE

 

15 March 2016

 

  1. Summary

 

The Pharmaceutical Benefit Advisory Committee (PBAC) met on 15 March 2016 to consider applications for changes to the Prescribed List.

 

1.1    The PBAC recommended the addition of one new medicine to the Prescribed List, as follows:

1.1.1        Cefixime Tablet 200mg

 

1.2    The following four formulations of medicines already included in the Prescribed List were also recommended:

1.2.1        Levodopa/carbidopa/entacapone 175/43.75/200 (Stalevo 175) tablet

1.2.2        Omeprazole 10mg orodispersible tablets (paediatric use only)

1.2.3        Exenatide modified-release 2mg injection (Bydureon)

1.2.4        Dimeticone 4% Lotion

 

1.3    The Committee recommended removal from the Prescribed List of the following medicines:

1.3.1        Omega-3 ethyl esters (Omacor)

1.3.2        Permethrin 1% crème rinse

1.3.3        Discontinued items – see appendix 2

 

1.4    The Committee recommended that the following, patent-expired medicines, should now be included in the Prescribed List as ‘Generic Only’ items:

1.4.1        Morphine Sulphate modified release tablets

 

1.5    In addition, the Committee recommended minor amendment of existing entries in the Prescribed List for:

1.5.1        Permethrin dermal cream 5% (to specify 5% strength)

1.5.2        Sudocrem cream (to remove erroneous 25mg strength)

 

1.6    Applications for one product to be added to the Prescribed List was not supported:

1.6.1        Fluticasone propionate 50mcg/Azelastine hydrochloride 137mcg (brand name Dymista)

 

 

The overall financial impact of these changes to the Prescribed List was considered to be a reduction in total expenditure of around £80,000, driven largely by the removal of Omacor from the Prescribed List. The addition of the small number of new products was believed to have little impact on total prescription costs.

 

Mrs Alison Creed

Chair, PBAC

 

15 April 2016

  1. Recommendations
    1.   Items to be added to the Prescribed List

 

2.1.1

Cefixime Tablet 200mg

Cefixime is a cephalosporin-type antibiotic. It is recommended in national guidelines for the management of common infections in primary care as a 2nd line option in children with upper urinary tract infections.

.

2.1.2

Levodopa/carbidopa/entacapone 175/43.75/200 (Stalevo 175) tablet

This combination product for the treatment of Parkinson’s disease is already included in the Prescribed List with a range of strengths except the ‘175’ strength. Addition will ensure that the full range of strengths is available for patients.

2.1.3

Omeprazole 10mg orodispersible tablets (paediatric use only)

Omeprazole is a proton-pump inhibitor used to reduce the secretion of stomach acid and used to treat acid reflux and gastro-intestinal ulcers. The Committee noted that there is currently no product of this therapeutic type in an easy to swallow form that is licensed for use in children. The Committee agreed that, though more expensive that standard oral forms of omeprazole, restricting use to children only will not cause a substantial increase in expenditure.   

2.1.4

Exenatide modified-release 2mg injection (Bydureon)

Exenatide is used for the treatment of type II diabetes. The Committee noted that this ‘slow-release’ formulation of an injectable product already in the Prescribed List. It is recommended for use by NICE. The cost of the ‘slow-release’ product is marginally more expensive than the standard product, which would be encouraged for use in the first instance.

2.1.5

Dimeticone 4% Lotion

The Committee accepted the recommendation for this evidence-based treatment for head-lice, which is a more effective replacement for the product currently included in the Prescribed List.

 

 

2.2 Items not recommended for addition to the Prescribed List

 

2.3.1

Fluticasone propionate 50mcg/Azelastine hydrochloride 137mcg (brand name Dymista)

This nasal spray for the treatment of hayfever has been previously considered and rejected by PBAC. The Committee again considered it to offer no compelling advantage over existing treatments that could justify its additional cost.

 

 

 

 


Appendix 1: Estimated financial impact of applications

 

 

 

Estimated annual expenditure

2.1.1

Cefixime Tablet 200mg.

<£1,000

2.1.2

Levodopa/carbidopa/entacapone 175/43.75/200 (Stalevo 175) tablet

No change

2.1.3

Omeprazole 10mg orodispersible tablets (paediatric use only)

<£1,000

2.1.4

Exenatide 2mg injection (Bydureon)

<£5,000

2.1.5

Dimeticone 4% Lotion

No change

 

 


Appendix 2

 

Discontinued items to be removed from the Prescribed List

  • Amphoteracin 10mg lozenges –
  • Becodisks
  • Benzatropine tablets and injection
  • Benzylpenicillin 0.5MU & 1MU
  • Betnesol-N eye ointment
  • Betnovate-C (all preparations)
  • Cabergoline 4mg tablets
  • Calcipotriol cream
  • Calcium lactate gluconate effervescent tablets
  • Calcium polystyrene sulphonate retention enema
  • Carbaryl
  • Cetomacrogol cream
  • Cicatrin (all preparations)
  • Cimetidine injection
  • Clomipramine liquid
  • Clonidine 300mcg tablets
  • Co-amoxiclav soluble tablets
  • Compound coconut oil ointment
  • Cortisone acetate tablets
  • Dipivefrine eye drops
  • Distigmine tablets
  • Domperidone suppositories
  • Econazole / hydrocortisone cream
  • Edrophonium
  • Ergocalciferol injection (IM)
  • Estradiol vaginal tablet 25mcg / 0.01% cream
  • Estriol pessary
  • Estropipate
  • Famciclovir 750mg
  • Fenbufen
  • Flexible collodion
  • Flurbiprofen M/R
  • Fluticasone diskhaler
  • GTN SA tablets
  • Haloperidol 500mcg/5ml liquid
  • Hydrocortisone / Crotamiton cream
  • Hydrous ointment BP
  • Ketoprofen 100mg caps
  • Levobunolol 1.4% PF eye drops
  • Lithium carbonate tablets 200mg & 400mg
  • Locorten vioform ear drops
  • Megestrol 40mg
  • Meloxicam suppositories
  • Metolazone
  • Mexenone
  • Mianserin 20mg tablets
  • Nabumentone suspension
  • Nalidixic acid suspension
  • Neomycin ointment 0.5%
  • Nicotinamine
  • Nystatin cream & ointment
  • Otosporin ear drops
  • Pentazocine sup
  • Physostigmine eye drops
  • Piperazine & senna powder
  • Procainamide tablets
  • Prontoral
  • Salicylic acid collodion & powder
  • Salmeterol diskhaler
  • Secobarbital
  • Senna granules
  • Silicone cream
  • Slow Fe Folic
  • Sodium bicarbonate eye lotion
  • Sodium fluoride drops / mouthwash / tablets
  • Sulphur BP
  • Syrup simplex BP
  • Triamcinolone / Gramicidin / neomycin / nystatin otic ointment
  • Triclofos
  • Trifluoperazine IM
  • Vioform
  • Zinc sulphate eye drops
  • Zinc sulphate injection
  • Zinc undecanoate injection

 

1

 

Back to top
rating button